Skip to main content
. 2014 May-Jun;89(3):436–440. doi: 10.1590/abd1806-4841.20142613

TABLE 3.

Frequency of use of other therapeutic modalities before and during treatment with anti-TNFα agents

    During anti-TNFα treatment   Before anti-TNFα treatment   p-value*
Methotrexate     42 (56.75%)     65 (87.83%)   0.00116
Acitretin     0 (0%)     33 (44.59%)   0.00011
Cyclosporine     0 (0%)     33 (44.59%)   0.00011
PUVA     1 (1.35%)     19 (25.67%)   0.00000
*

McNemar's Test